Pfizer said Wednesday that its rheumatoid arthritis drug, Xeljanz, reduced death or respiratory failure in hospitalized patients with COVID-19 pneumonia in Brazil, meeting the main goal of the study.
–
Pfizer rheumatoid arthritis drug is beneficial in COVID-19 pneumonia – STUDY
–
–
Pfizer said the incidence of death or respiratory failure was 18.1% in patients treated with the drug, compared to 29% in others. Serious side effects have occurred in 20 patients treated with the drug, according to Reuters.
Xeljanz, which belongs to a class of drugs called JAK inhibitors and also treats ulcerative colitis of autoimmune disease, has not been approved for use in any country for COVID-19 treatment to date.
Pfizer and German partner BioNTech have created one of three currently approved and used COVID-19 vaccines.
The results of the study, which tested the drug in 289 adult patients hospitalized with respiratory disease caused by coronavirus, were published in the New England Journal of Medicine.
–
For the most important news of the day, broadcast in real time and presented equidistantly, LIKE our Facebook page!
Follows Mediafax on Instagram to see spectacular images and stories from around the world!
The content of the website www.mediafax.ro is intended exclusively for your personal information and use. It is prohibited republishing the content of this site in the absence of an agreement from MEDIAFAX. To obtain this agreement, please contact us at [email protected].
PHOTO. What Maria Constantin looks like after the last bust augmentation operation!
TACATACA.PROSPORT.RO
–
The doctors were shocked! What a woman has introduced into her genitals surpasses any imagination
CANCAN.RO
–
